Schizophrenia Clinical Trial
— FaSchi22Official title:
Facial Expression Perception by Intensity in Schizophrenia and 22q11.2 Deletion Syndrome: Neural Electrophysiological Evidence by Means of Fast Periodic Visual Stimulation
Verified date | February 2018 |
Source | Hôpital le Vinatier |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background:
The present study aims to identify the mechanisms underlying the deficit in facial emotion
recognition reported both in schizophrenia and the 22q11.2 deletion syndrome, and thus,
reveal a distinction between the two disorders. Indeed, despite the clinical overlap between
the two syndromes, some of the symptoms appear to be specific to only one of them. In
particular, the disturbance of visual functions is specifically observed in the 22q11.2DS.
Hence, the difficulties in facial emotion recognition in schizophrenia and in the 22q11.DS
are likely accounted by different cognitive impairments. Investigating which mechanisms are
disturbed would allow a specialized support for patients.
Our main hypothesis is that the deficit in facial emotion recognition is more related to
visual impairments in the 22q11.2DS than in schizophrenia. This hypothesis will be tested in
two groups of patients (22q11.2DS and schizophrenic patients) and a control group (healthy
subjects) using an experimental paradigm based on electroencephalography (EEG).
A second aim of this study is to determine whether the severity of the two disorders'
symptoms is correlated with the cerebral response to facial expressions. To answer this
question, a set of clinical and neuropsychological tests will be conducted for each patient.
Status | Completed |
Enrollment | 70 |
Est. completion date | December 30, 2017 |
Est. primary completion date | October 20, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 15 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Aged 15-50 years old - No psychiatric conditions or comorbidity - Agreement from parents if participant is underage - Patients with schizophrenia: diagnosis assessed with DSM5 criteria - Patients with 22q11.2 DS: diagnosis assessed by genetic tests (CGH- array or FISH) - No mental delay (IQ>70 according to the fNART) - No modification of psychotropic treatment during the month before inclusion Exclusion Criteria: - Involvement in a current program of social cognition remediation - Pregnancy - Substance use disorder (criteria of DSM-5), except for caffeine and tobacco - Neurologic disorders (vascular, infectious or neurodegenerative) - Uncorrected visual deficit - Guardianship - Medical drugs with cerebral or psychological effect (e.g, corticosteroids) - Resistance to antipsychotics - Electroconvulsive therapy in the previous two months |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Hôpital le Vinatier |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Steady-state visual evoked potentials (SSVEP) recorded during fast periodic visual stimulation (FPVS). | SSVEPs arise in response to the periodic presentation of emotional faces. They are analyzed in the frequency domain. Two types of responses are expected: the general visual response (6 Hz and its harmonics) and the expression-specific response (1.2 Hz and its harmonics). Both responses will be compared across the different groups. | SSVEPs will be recorded during 20 sequences of emotional faces pictures. As each sequence lasts 80s, the EEG recording will be approximately 30-minutes-long. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |